Navigation Links
Mark & Associates, P.C. & McGinnis, Lochridge, Kilgore, L.L.P. File Lawsuit Against Botox Maker Over Patient Deaths, Injuries

UNIONDALE, N.Y., July 10 /PRNewswire/ -- Mark & Associates, P.C. and McGinnis, Lochridge, Kilgore, L.L.P., have filed a civil lawsuit today against Botox-maker Allergan, Inc. (NYSE: AGN) for negligent failures in the design, manufacturing and marketing of the popular anti-wrinkle drug that has caused patient deaths and injuries. The suit, filed in the Superior Court of California, Orange County, (Case No. 00180033) on behalf of 15 plaintiffs from across the nation, seeks unspecified compensatory and punitive damages. Allergan is based in Irvine, California. A copy of the complaint is available at

In addition to alleging design and manufacturing flaws, the suit claims that Allergan continues to promote "off label" uses of Botox for treating patients with cerebral palsy and other uses that have not been approved by the Food and Drug Administration. Allergan also fails to properly warn Botox users of the possibility of fatal and life-threatening injuries from Botox injections and fails to inform physicians and health care providers about all known risks of the drug, including death.

Ray Chester, lead counsel in the Botox litigation from McGinnis, Lochridge, Kilgore, L.L.P., and Jason Mark from Mark & Associates, P.C., continue to evaluate cases involving Botox deaths and injuries on behalf of patients who used the drug for cosmetic and therapeutic purposes. Free case consultations are available by calling 1-866-50-RIGHTS (1-866-507-4448) or by completing an inquiry on

Select Plaintiff Profiles

-- A seven-year-old girl from Amarillo, Texas who died in 2007 after receiving Botox injections intended to treat her limp spasticity, caused by cerebral palsy. The girl developed pneumonia after undergoing Botox treatments and died. The suit is being brought on behalf of the girl's mother who is suing for damages from the death of her daughter.

-- A four-year-old boy from Maryland who died in 2007 after undergoing Botox treatments. His parents have filed suit on behalf of their deceased son.

-- A sixty-nine-year-old woman who died in March 2008 after undergoing Botox treatments. The victim, a registered nurse, received Botox injections in 2007 in an attempt to lessen neck and shoulder pain. Following a series of Botox treatments, she developed severe dysphasia, lost about 50 pounds, and died of aspiration and malnutrition. Her children are suing for the death of their mother.

-- A New Jersey man who died in April, 2008 as a result of Botox injections. The man's brother has filed suit on behalf of his deceased brother.

What is Botox?

The active ingredient in Botox is Botulinum Toxin A, a purified and diluted form of botulism, which causes muscle paralysis. By temporarily stopping muscle movement, Botox can be effective in reducing the appearance of wrinkles in the skin, particularly around the eyes, nose and mouth. Botox is approved for cosmetic uses and select medical indications, including: Cervical dystonia, Blepharospasm, Strabismus, and excessive underarm sweating.

FDA Has Warned of Botox Dangers

In February 2008, the Food and Drug Administration issued a public health warning to consumers and health care providers after receiving reports of deaths, breathing problems, and other adverse reactions caused by Botox. Many of the deaths and injuries involved unapproved, "off label" uses of Botox in cerebral palsy patients suffering from muscle spasms. "Botulinum toxin is one of the most potent neurotoxins known, and injecting it at high doses is simply inviting catastrophe. The manufacturer's promotion of that practice without properly informing patients and the medical community of the potential consequences is outrageous," commented Jason Mark, the founding partner of Mark & Associates.

About Mark & Associates, P.C.

Mark & Associates, P.C. has offices in Boston, Massachusetts and Long Island, New York. The firm aggressively represents victims of securities and investment fraud, insurance bad faith, defective products, dangerous pharmaceuticals and medical devices and serious accidents. More information on Mark & Associates, P.C. is available at

About McGinnis, Lochridge, Kilgore, L.L.P.

McGinnis, Lochridge, Kilgore, L.L.P. is a multi-practice Texas law firm with offices in Austin and Houston. The firm has earned a prominent reputation for professional excellence by guiding its clients to pragmatic solutions in lawsuits, business, and government. For over 75 years, clients have relied on the firm's talent, experience, and strength to achieve their goals and protect their interests.

SOURCE Mark & Associates, P.C.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
4. MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012
5. MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors
6. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
7. Shareholder Class Action Filed Against Health Management Associates, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. MQ Associates, Inc. Announces Expiration of its Tender Offers for its 12 1/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Medquest, Inc.s 11 7/8% Senior Subordinated Notes Due 2012 (CUSIP No. 58505DAD1)
9. National HealthCare Recognized for Outstanding Sales Leadership by Long Term Care Associates, Inc.
10. MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007
11. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: